ZBIO
Zenas BioPharma, Inc. (NASDAQ)
Healthcare — Biotechnology
Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc?RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus. The company develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a CTLA-4-Ig fusion protein designed to have an extended half-life versus; and ZB001, an anti-IGF-1R monoclonal antibody. The company was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is headquartered in Waltham, Massachusetts.
Price History
Fundamentals
| Market Cap | $1.78B |
| P/E Ratio (TTM) | - |
| Forward P/E | -12.46 |
| EPS (TTM) | $-9.10 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | -137.11% |
| Debt/Equity | 79.45 |
| Recommendation | None |
| Analyst Target | $42.13 |
| Analysts | 8 |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 83.0 |
| Beta | - |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $44.60 |
| 52-Week Low | $9.21 |
| 50-Day Avg | $19.67 |
| 200-Day Avg | $24.86 |
| Avg Volume | 692.0K |
| Volume | 4.7K |
Performance Analysis
NEUTRALZBIO presents a mixed picture with both positive and negative indicators.
Recent News
Last updated: Jul 02, 2026 13:39 UTC
Back to Screener Export Report